



(51) International Patent Classification:

C07C 57/13 (2006.01) *C09K 19/38* (2006.01)
C07C 69/602 (2006.01) *C09K 19/02* (2006.01)

(21) International Application Number:

PCT/US2013/022701

(22) International Filing Date:

23 January 2013 (23.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/589,574 23 January 2012 (23.01.2012) US

(71) Applicant: **WISCONSIN ALUMNI RESEARCH FOUNDATION** [US/US]; 614 Walnut Street, 13th Floor, Madison, Wisconsin 53726 (US).

(72) Inventors; and

(74) Applicants (for US only): **MAHANTHAPPA, Mahesh Kalyana** [US/US]; 530 W. Doty Street, Unit 303, Madison, Wisconsin 53706 (US). **SORENSEN, Gregory Paul** [US/US]; 2030 Fish Hatchery Road, Apt. 16, Madison, Wisconsin 53713 (US).







(74) Agent: **LECUYER, Karen A.**; CANTOR COLBURN LLP, 20 Church Street, 22nd Floor, Hartford, Connecticut 06103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: POLYMERIZABLE GEMINI DICARBOXYLATE SURFACTANTS AND LYOTROPIC LIQUID CRYSTALS AND MEMBRANES MADE THEREFROM



(57) Abstract: The disclosure provides anionic Gemini surfactants comprising at least two carbonyl moieties and at least two aliphatic moieties. In some aspects, at least two of the aliphatic moieties comprise at least seven carbon atoms and at least one pair of conjugated carbon-to-carbon double bonds. The anionic Gemini surfactants are polymerizable and may be used to prepare triply periodic multiply continuous lyotropic phase and polymers thereof that substantially retain triply periodic multiply continuous lyotropic phase structure.



Published:

— *with international search report (Art. 21(3))*

POLYMERIZABLE GEMINI DICARBOXYLATE SURFACTANTS AND LYOTROPIC LIQUID CRYSTALS AND MEMBRANES MADE THEREFROM

REFERENCE TO CROSS-RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application 61/589,574 filed on January 23, 2012, which is incorporated herein by reference in its entirety.

FIELD OF THE DISCLOSURE

[0002] The field of the disclosure relates generally to polymerizable Gemini surfactants and polymers and lyotropic liquid crystals prepared therefrom.

BACKGROUND

[0003] Aqueous lyotropic liquid crystal (LLC) assemblies have garnered widespread attention in disparate areas of chemistry, by virtue of their utility in highly selective chemical separations such as water desalination and selective ion-transporting membranes, as templates for mesoporous inorganic materials, as media for biophysical studies of transmembrane proteins (“cubic lipidic phases”), and as therapeutic nucleic acid delivery vehicles. LLCs form by the concentration-dependent supramolecular self-organization of amphiphilic molecules in water into soft materials having distinct hydrophilic and hydrophobic nanoscale domains (approximately 7 to 100 Å) with long-range periodic order. LLCs typically exhibit ordered phases such as lamellae (L_α), bicontinuous cubic (Q; e.g., double gyroid, double diamond, and “Plumber’s Nightmare”), hexagonally packed cylinders (H), and discontinuous cubic (I; e.g., body-centered cubic) morphologies. High symmetry Q-phase assemblies, exemplified by the gyroid (G) phase, are particularly desirable for membrane applications by virtue of their interpenetrating aqueous and hydrophobic domains with tunable nanopore diameters (approximately 7 to 50 Å) and well-defined nanopore functionalities that percolate over macroscopic lengthscales. Q-phases typically exist only in limited water concentration and temperature phase windows, due to the fact that their interfaces substantially deviate from a constant mean interfacial curvature. While “critical packing parameter” models enable correlations of amphiphile structure with the formation of constant mean curvature L_α , H, and I phases, these models fail to provide reliable and general molecular design criteria for amphiphiles that form non-constant mean curvature Q phases. It was recently reported that small molecule quaternary ammonium,


phosphonium, and imidazolium Gemini amphiphiles, derived from dimerizing single-tail surfactants with an alkyl spacer through the ionic headgroup, exhibit a greater tendency to form G phase LLCs. The notion that Gemini architectures universally form bicontinuous cubic LLC morphologies remains an untested amphiphile design principle.

[0004] In order to advance applications of LLC assemblies for membrane filtration, ion conduction, and other transport processes, increased attention has been devoted to polymerizable triply periodic multiply continuous LLCs. The weak non-covalent forces stabilizing these supramolecular assemblies render them soft and mechanically inferior. Also, their concentration dependent phase behavior limits their potential utility in solution-phase molecular sieving for aqueous separations. By installing polymerizable functionalities in the surfactant structure, a LLC assembly may be covalently fixed in place by thermal or photo- polymerization to yield a robust polymeric network with retention of the triply periodic structure. The low dimensionality of L_{α} -phases and H-phases requires domain alignment at macroscopic lengthscales in order to achieve transport through either the hydrophilic or hydrophobic domains of an LLC. However, the high symmetry and three-dimensional structural periodicity of the interpenetrating domains of triply periodic multiply continuous phases result in percolating domains that do not require alignment. By virtue of their construction, the hydrophilic and hydrophobic domains of LLCs have dimensions d of approximately 5-100 Å with domain interfaces that are decorated with well-defined chemical functionalities. The dimensions of the water-filled channels are approximately one order of magnitude smaller than those in nanoporous block copolymers (d approximately 50-1000 Å), enabling applications including water desalination, ultrafiltration, selective ion transport.

[0005] What is needed are additional molecules that can assemble to form LLC assemblies.

SUMMARY

[0006] Briefly, therefore, the present disclosure is directed to a polymerizable molecule having the following structure:



wherein X_1 and X_2 are each independently an optionally substituted branched, unbranched, or cyclic aliphatic group having from four to 30 carbon atoms;

Z_1 and Z_2 are integers, each independently having a value of zero, one, two, or three;


Y is a covalently bound divalent linker;

M_1 and M_2 are the same or different and are each independently selected from hydrogen, hydroxyl, $-O(C_1-C_8 \text{ alkyl})N(CH_3)_3^+(X^-)$ where X^- is a counterion, $-(C_0-C_8 \text{ alkyl})NR_{11}R_{12}$, $-O(C_1-C_8 \text{ alkyl})NR_{11}R_{12}$, $-NH(C_1-C_8 \text{ alkyl})NR_{11}R_{12}$, $-NH(CH-R_{13})COOH$, $-OR_{11}$, $-NR_{11}R_{14}$, and $-O^-(M^+)$ where M^+ is a counterion, wherein R_{11} , R_{12} , and R_{14} are independently chosen from hydrogen and optionally substituted C_1-C_8 alkyl, and wherein R_{13} is an amino acid side chain;

and R_1 through R_{10} are each independently selected from hydrogen, fluoride, chloride, bromide, C_1-C_8 alkyl, C_2-C_8 alkenyl, tri(C_1-C_4 alkyl)silyl, and substituted or unsubstituted phenyl.

[0007] In certain embodiments R_{11} and R_{14} are C_1-C_8 alkyl substituted with at least one substituent chosen from hydroxyl, $-SO_3H$, $-OSO_3H$, and $-PO_3H_2$, resulting in an M_1 or M_2 group that is, for example, $-OCH_2CH(OH)CH_2OH$, $-NH(C_1-C_8 \text{ alkyl})SO_3H$, $-N(CH_3)(C_1-C_8 \text{ alkyl})SO_3H$, $-O(C_1-C_8 \text{ alkyl})SO_3H$, $-NH(C_1-C_8 \text{ alkyl})OSO_3H$, $-N(CH_3)(C_1-C_8 \text{ alkyl})OSO_3H$, $-O(C_1-C_8 \text{ alkyl})OSO_3H$, $-NH(C_1-C_8 \text{ alkyl})PO_3H_2$, $-N(CH_3)(C_1-C_8 \text{ alkyl})PO_3H_2$, or $-O(C_1-C_8 \text{ alkyl})PO_3H_2$.

[0008] The disclosure is further directed to a method of preparing a Gemini surfactant. The method comprises (a) contacting a carboxylic acid, a carboxylate salt, or a carboxylate ester with a quantity of a base to thereby deprotonate the alpha carbon of the carboxylic acid, a carboxylate salt, or a carboxylate ester, wherein the carboxylic acid, a carboxylate salt, or a carboxylate ester comprises at least seven carbon atoms and at least one carbon-to-carbon double bond; and (b) contacting the alpha carbon-deprotonated carboxylic acid, a carboxylate salt, or a carboxylate ester with a compound having the structure:



wherein L_1 and L_2 comprise leaving groups, Y comprises a covalently bound divalent linker, whereby said contact forms the Gemini surfactant.

[0009] The disclosure is still further directed to a method of preparing a Gemini surfactant comprising a terminal diene. The method comprises contacting a Gemini dicarboxylate compound with an oxidizing agent to thereby prepare a Gemini dialdehyde; and contacting the Gemini dialdehyde with an (1-trialkylsilyl)allyl-3-boronic acid or an ester thereof, which contact is followed by silanol elimination reaction with an acid or a base to thereby prepare the Gemini surfactant comprising the terminal diene.

[0010] The disclosure is still further directed to a method of preparing a polymer. The method comprises contacting an anionic Gemini surfactant with a polymerization initiator to thereby prepare the polymer, wherein the anionic Gemini surfactant comprises at least two carboxylate moieties and at least two aliphatic moieties, wherein at least two of the aliphatic moieties comprise at least seven carbon atoms and at least one pair of conjugated carbon-to-carbon double bonds.

[0011] The disclosure is still further directed to a polymer comprising a polymerized anionic Gemini surfactant; wherein the polymerized anionic Gemini surfactant is polymerized from an anionic Gemini surfactant comprising at least two carboxylate moieties and at least two aliphatic moieties, wherein at least two of the aliphatic moieties comprise at least seven carbon atoms and at least one pair of conjugated carbon-to-carbon double bonds.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] FIGS. 1A through 1F are illustrations of the observed LLC morphologies formed by Gemini surfactants: hexagonal (H_I) with constant positive mean curvature (FIG. 1A), lamellar (L_a) with flat interfaces (FIG. 1B), Gyroid (G_I) (FIG. 1C), Double Diamond (D_I) (FIG. 1D), Primitive (P_I) (FIG. 1E), and tetracontinuous hexagonal (FIG. 1F) that require substantial positive and negative deviations from constant mean curvature.

[0013] FIGS. 2A through 2C are illustrations of the variety of possible curvatures adopted by Gemini surfactants with flexible hydrophobic alkyl spacers.

[0014] FIG. 3 depicts azimuthally integrated X-ray diffraction patterns of a lyotropic liquid crystal (LLC) based on 65 wt% 4, 0.4 wt % 2,2-dimethoxy-2-phenylacetophenone, and 34.6 wt% H_2O . The LLC was prepared as set forth in Example 2.

The polymerizable surfactant forms a gyroid phase before UV crosslinking (bottom curve). The XRD of the LLC after UV crosslinking polymerization (upper curve) demonstrates retention of the gyroid morphology with a slight reduction in the unit cell dimensions.

[0015] FIG.4 is an optical micrograph of the film resulting from UV crosslinking of the LLC derived polymerizable Gemini surfactant 4.

DETAILED DESCRIPTION


[0016] The present disclosure is directed to novel polymerizable Gemini surfactants that can form lyotropic liquid crystals. Lyotropic liquid crystals are comprised of materials that form phases having long-range translational order induced by the addition of a solvent. Stated another way, lyotropic liquid crystals include ordered phases in solvent, in which the structurally periodic phase that exists in the liquid crystal composition varies as a function of concentration of the surfactant in the solvent system, temperature, and pressure. A subset of these phases can be described as being triply periodic, since the phases comprise structures that repeat in three dimensions. LLC phases may be described in a phase diagram in which the X-axis (abscissa) is concentration and the Y-axis (ordinate) is temperature. The liquid crystalline phase that generally forms at low surfactant concentrations is the “micellar cubic” or “discontinuous cubic” phase comprising spherical micelles and which may be denoted by the symbol I_1 . This is a viscous, optically non-birefringent phase in which the micelles are arranged on a cubic lattice. At higher concentrations, in general, the cylindrical micelles of indefinite length form and are arranged on a two-dimensional hexagonal lattice with long-range periodic order. This lyotropic liquid crystalline phase is known as the “hexagonal phase”, or more specifically the “normal” hexagonal phase and is generally denoted by the symbol H_1 . At higher concentrations, the “lamellar phase” generally forms. This phase is denoted by the symbol L_a . This phase consists of surfactant molecules arranged in bilayer sheets separated by layers of solvent. Some materials may form an intermediate phase at concentrations generally between those concentrations at which hexagonal and lamellar phases form. Some intermediate phases may be referred to as bicontinuous cubic phases or Q-phases. Bicontinuous cubic phases include gyroid phase (G_1 , space group #230), the double diamond phase (space group #224), and the primitive cubic phase (space group #229). See FIGS. 1A through 1F. FIGS. 1A through 1F depicts the Hexagonal (H_1) (FIG. 1A), Lamellar (L_a) (FIG. 1B), and Gyroid (G_1) (FIGS. 1C through 1E) phases. FIG. 1F depicts a tetracontinuous hexagonal phase, which may be prepared using anionic Gemini surfactants of the present disclosure. The various phases that a lyotropic liquid crystal may assume are

generally discussed as a function of concentration; however, phase transitions may occur as the temperature or pressure of the system increases. Surfactant concentrations at which a gyroid phase, for example, may form at lower temperatures, e.g., 20°C, may shift or the range may narrow as the temperature of the system increases, e.g., to 100°C.

[0017] The present disclosure is directed to polymerizable anionic Gemini surfactants comprising at least one carboxylate moiety, preferably two carboxylate moieties, that robustly form lyotropic liquid crystals upon the addition of a solvent. The polymerizable anionic Gemini surfactants of the present disclosure form triply periodic multiply continuous lyotropic phases over broad ranges of concentration and temperature. These triply periodic multiply continuous phases encompass bicontinuous cubic phases, for example, the gyroid phase (space group #230), double diamond phase (space group #224), or primitive cubic phase (space group #229). The triply periodic multiply continuous phases of the present disclosure additionally encompass tetracontinuous phases, such as a novel hexagonal tetracontinuous phase (space group #193) with percolating pores in three dimensions. This phase is comprised of three distinct, interpenetrating, and unconnected hydrophobic networks each having $P6_3/mmc$ (space group #194) symmetry to yield an overall hydrophobic network structure with $P6_3/mcm$ symmetry (space group #193), in which the voids are filled with solvent. This tetracontinuous phase is related yet distinct from that described previously in mesoporous silicates.

[0018] The polymerizable anionic Gemini surfactants of the present disclosure are particularly useful for membrane applications of lyotropic liquid crystals since the surfactants are capable of being chemically fixed in place by crosslinking polymerization, e.g., chemical crosslinking polymerization, to form mechanically robust membranous materials. Such mechanically robust materials may find particular use in separations, catalysis, and selective ion transport.

[0019] The polymerizable anionic Gemini surfactants additionally comprise multiple, preferably two, hydrophobic tail groups, the tail groups being linked via a covalently bound divalent linker, Y, generally bonded to the alpha carbon of the carboxylic acids. A polymerizable anionic Gemini surfactant according to the present disclosure has the following structure (I):



[0020] In structure (I), X_1 and X_2 are each independently an optionally substituted branched, unbranched, or cyclic aliphatic group having from four to 30 carbon atoms, specifically from four to 20 carbon atoms, even more specifically from four to 16 carbon atoms, such as from four to nine carbon atoms. The X_1 and X_2 aliphatic groups may be saturated or may comprise unsaturated moieties, such as alkenyl or alkynyl. That is, the X_1 and X_2 aliphatic groups may comprise one or more carbon-to-carbon double bonds and/or one or more carbon-to-carbon triple bonds. Additionally, the X_1 and X_2 aliphatic groups may comprise cyclic moieties, i.e., cycloalkyl, either within the main carbon chain or branched therefrom. The X_1 and X_2 aliphatic groups may comprise branching moieties, e.g., alkyl, alkenyl, trialkylsilyl, phenyl, and substituted phenyl. The X_1 and X_2 aliphatic groups may comprise hydrocarbyls (i.e., the entirety of the aliphatic group comprises only carbon-carbon or carbon-hydrogen bonds) or the aliphatic groups may comprise heteroatom substituents, such as halide atoms (e.g., fluoride, chloride, and bromide) bonded to carbon atoms. In some embodiments, the aliphatic groups contain at least two fluoride atoms, such as at least four fluoride atoms. In some embodiments, the aliphatic groups are perfluorinated, meaning that all hydrogen atoms along the carbon chain are replaced with fluoride atoms.

[0021] In specific embodiments, the X_1 and X_2 aliphatic moieties comprise at least one carbon-to-carbon double bond. In other embodiments, each of the X_1 and X_2 aliphatic moieties comprise at least two carbon-to-carbon double bonds, wherein the carbon-to-carbon double bonds are separated by at least one methylene group, such as one methylene group, two methylene groups, three methylene groups, or more. Anionic Gemini surfactants comprising long, saturated aliphatic chains tend to have a high degree of crystallinity, which may shorten the concentration ranges over which the surfactants form triply periodic multiply continuous phases. Double bonded moieties advantageously disrupt the crystal-forming

tendencies of long aliphatic chain surfactants, thereby extending the triply periodic multiply continuous phase concentration and temperature ranges.

[0022] In a specific embodiment, X_1 and X_2 are both C_2 to C_{20} alkyl, specifically C_2 to C_{10} alkyl, and more specifically C_4 - C_7 alkyl, any of C_4 , C_5 , C_6 , or C_7 alkyl.

[0023] In structure (I), Z_1 and Z_2 are integers, each independently having a value of zero, one, two, or three. In specific embodiments of the present disclosure, Z_1 and Z_2 are each independently zero or one. In some embodiments of the present disclosure, Z_1 and Z_2 are both one.


[0024] In structure (I), R_1 through R_{10} are each independently selected from the group consisting of hydrogen, fluoride, chloride, bromide, C_1 to C_8 alkyl, C_2 to C_8 alkenyl, tri(C_1 - C_4 alkyl)silyl, and substituted or unsubstituted phenyl. In one embodiment, the alkyl and alkenyl moieties have 1 to 4 carbon atoms. Trialkylsilyl has the general structure R_3Si , wherein the R is selected from methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, and combinations thereof. In some embodiments, each of R_1 through R_{10} is independently chosen from hydrogen and halogen. In certain embodiments each of R_1 through R_{10} is hydrogen. In embodiments wherein the X_1 and X_2 aliphatic moieties are perfluorinated, each of R_1 through R_{10} is fluoride.

[0025] In structure (I), Y is a covalently bound divalent linker. In some embodiments, Y comprises an optionally substituted C_1 - C_{20} aliphatic group, an optionally substituted C_1 - C_{20} heteroaliphatic group, which aliphatic and heteroaliphatic groups may be branched, unbranched, or cyclic.

[0026] When Y is an aliphatic group it comprises a group of three carbon atoms to 20 carbon atoms, such as a group of three carbon atoms to 8 carbon atoms. An "aliphatic group" may be saturated or unsaturated hydrocarbon group such as an alkyl, alkenyl or alkynyl group, or a non-aromatic cyclic group, such as a cyclohexane, or may contain both a non-aromatic cyclic group and an acyclic hydrocarbon chain. A "heteroaliphatic group" is an aliphatic group in which one or more carbons in the aliphatic group has been replaced with a heteroatom independently chosen from N, O, S, and P. In some embodiments, Y comprises heteroatoms, such as oxygen, that increase the hydrophilicity of the covalently bound divalent linker, Y. Heteroaliphatic linkers may increase hydrophilicity or alter linker conformations to enable formation of triply periodic multiply continuous phase stabilization with different stabilities. The aliphatic or heteroaliphatic group may be substituted with substituents such as, but not limited to, halogen, hydroxyl, amino, cyano, -CHO, -COOH, alkoxy, alkanoyl, aminoalkyl, alkylcarboxamide, and alkylester.

[0027] In some specific embodiments, Y comprises an unsubstituted branched or unbranched aliphatic group comprising three to 20 carbon atoms, such as three to 12 carbon atoms, or three to eight carbon atoms. Aliphatic linkers, including acyclic aliphatic linkers provide a large degree of flexibility to the connection. Flexible hydrophobic spacers confer conformational flexibility that enables the surfactant to accommodate the substantial deviations from constant mean interfacial curvature required for triply periodic multiply continuous phase stabilization. See FIGS. 2A through 2C for illustrations of the curvatures afforded by flexible aliphatic connecting moieties, including positive curvature (FIG. 2A), flat curvature (FIG. 2B), and negative curvature (FIG. 2C).


[0028] In some embodiments, Y comprises an aryl or heteroaryl group, comprising one aromatic ring or a bi- or tri-cyclic fused rings system of which at least one ring is aromatic, wherein each aromatic ring in the aryl or heteroaryl group contains 5-6 ring atoms, with 0-4 heteroatoms independently chosen from N, O, and S with remaining ring atoms being carbon, and each non-aromatic ring in the aryl or heteroaryl group contain 3-7 ring atoms with 0 to 2 heteroatoms independently chosen from N, O, and S and remaining ring atoms being carbon, and wherein the aryl or heteroaryl group optionally comprises one or two C₁-C₅ aliphatic chains wherein the point of attachment of Y is a carbon in the C₁-C₅ aliphatic chain.. Rigid hydrophobic spacers alter conformational flexibility that enables formation of triply periodic multiply continuous phase stabilization with different stabilities. Aryl group substituents may include fluoride, chloride, bromide, methyl, ethyl, propyl, butyl hydroxyl, alkoxy generally having from one to four carbon atoms, nitro, and amines having the general structure -NH_xR, wherein x has a value from 0 to 2, and R may be an alkyl having from one to four carbon atoms. A heteroaryl group may be for example a pyridyl, pyrazolyl, furanyl pyrrolyl, thienyl, or imidazolyl group. The aliphatic chains extending from the aryl moiety generally have 0 to five carbon atoms, one to five carbon atoms, or one to three carbon atoms. The aliphatic chains may be located ortho, meta, or para to each other around the aromatic ring. In some embodiments, such a connecting moiety has the structure:



wherein n_1 and n_2 are integers, each having an independent value between 0 and five, between one and five, or between one and three. The aliphatic chains herein may be located ortho, meta, or para to each other around the aromatic ring.


[0029] In some embodiments, the hydrophilic moiety comprises a polyalkylether moiety, for example, a short polyethylene oxide or polypropylene oxide, generally having 1 to 4 repeat units.

[0030] In one embodiment, the connecting moiety is a poly(C_1 - C_3)alkylether moiety having 1 to 4 repeating units. In one embodiment, the hydrophilic moiety has the structure:




wherein n_3 is an integer having a value of one to four, such as one or two. This group may be optionally substituted.


[0031] In some embodiments, the hydrophilic connecting moiety contains hydroxyl or alkoxy substituents. Such a connecting moiety may have the structure:




wherein R_{15} and R_{16} are each independently hydrogen, hydroxyl, alkyl or alkoxy having from one to five carbon atoms; and n_4 is an integer having a value of one to ten, such as one to six, or one to three. One such hydrophilic moiety has the structure:



[0032] In further embodiments, linking group Y is



or



[0033] In one embodiment of structure (I), M_1 and M_2 are each independently a group $-O^-(M^+)$, where M^+ is a counterion, or another covalently bonded group as described herein. Without being held to theory, it is believed that the counterion in the polymerizable anionic carboxylate Gemini surfactants of the present disclosure, when present, also plays a role in enhancing the flexibility and the curvature of the surfactant. Effective charge neutralization through counterion associations with the headgroup allows the alkyl spacer between the carboxylate headgroups to relax, enabling the Gemini surfactant to adopt a wider range of interfacial curvatures over a broader range of headgroup hydration levels to stabilize the non-constant mean curvature G_I -phase. Exemplary M^+ counterions include among lithium ion; sodium ion; potassium ion; zinc ion; cesium ion; magnesium ion; calcium ion; ammonium ion; alkylammonium ion having the structure $H_xR_{4-x}N^+$ wherein x is an integer having a value of 0 through 4 and R is selected from the group consisting of methyl, ethyl, propyl, butyl, and combinations thereof; tetrakis(hydroxymethyl)phosphonium ion; tetramethylphosphonium ion; choline; imidazolium; bis(quaternary ammonium) ion, and combinations thereof. Alkylammonium ions may include, for example, methylammonium ion, dimethylammonium ion, trimethylammonium ion, ethylammonium ion, diethylammonium ion, triethylammonium ion, tetramethylammonium ion, and tetraethylammonium ion. Specific M^+ counterions include sodium ion, potassium ion, and tetramethylammonium ion.

[0034] In some embodiments, M_1 and M_2 are is a covalently bonded group, such as hydrogen, hydroxyl, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted mono- or di-alkylamino group, or an optionally substituted (mon- or di-alkylamino)alkyl group. Particular M_1 and M_2 groups include $-NH(CH-R_{13})COOH$, in which R_{13} is an amino acid side chain and $-NH(C_1-C_8\text{alkyl})SO_3H$. In some embodiments, M_1 or M_2 is an aliphatic group, e.g., an alkyl group, having one to eight carbon

atoms, or one to four carbon atoms, such as methyl, ethyl, isopropyl, n-propyl, isobutyl, n-butyl, or sec-butyl. In some embodiments, M is methyl. In some embodiments, M_1 and M_2 are the same or different and are each independently $-O^-(M^+)$ where M^+ is a counterion, or a M_1 and M_2 are a covalently bonded group selected from $-(C_1-C_8 \text{ alkyl})NR_{11}R_{12}-NH(CH-R_{13})COOH$, $-NH(C_1-C_8 \text{ alkyl})SO_3H$, or $-OR_{11}$ wherein R_{11} and R_{12} are independently chosen from hydrogen and optionally substituted C_1-C_8 alkyl, and R_{13} is an amino acid side chain. In specific embodiments, M_1 and M_2 are selected from the group consisting of sodium ions, potassium ions, and tetramethylammonium ions. In more specific embodiments, M_1 and M_2 are independently selected from the group consisting of hydroxyl, methoxy, $-ONa^+$, and $-OK^+$.


[0035] In some embodiments M_1 and M_2 are each independently $-O^-(M^+)$ where M^+ is a counterion, or M_1 and M_2 are each independently


[0036] (i) $-O(C_1-C_8 \text{ alkyl})N(CH_3)_3^+(X^-)$ where X^- is a counterion, $-(C_0-C_8 \text{ alkyl})NR_{11}R_{12}$, $-O(C_1-C_8 \text{ alkyl})NR_{11}R_{12}$, $-NH(C_1-C_8 \text{ alkyl})NR_{11}R_{12}$, $-NH(CH-R_{13})COOH$, $-OR_{11}$, $-NR_{11}R_{14}$, and $-O^-(M^+)$ where M^+ is a counterion, wherein R_{11} , R_{12} , and R_{14} are independently chosen from hydrogen and optionally substituted C_1-C_8 alkyl, and wherein R_{13} is an amino acid side chain; or

[0037] (ii) $-OCH_2CH(OH)CH_2OH$, $-NH(C_1-C_8 \text{ alkyl})SO_3H$, $-N(CH_3)(C_1-C_8 \text{ alkyl})SO_3H$, $-O(C_1-C_8 \text{ alkyl})SO_3H$, $-NH(C_1-C_8 \text{ alkyl})OSO_3H$, $-N(CH_3)(C_1-C_8 \text{ alkyl})OSO_3H$, $-O(C_1-C_8 \text{ alkyl})OSO_3H$, $-NH(C_1-C_8 \text{ alkyl})PO_3H_2$, $-N(CH_3)(C_1-C_8 \text{ alkyl})PO_3H_2$, or $-O(C_1-C_8 \text{ alkyl})PO_3H_2$.


[0038] Any of the definitions of M_1 and M_2 given herein in a discussion of the polymers may also be used in methods of making the polymers.

[0039] In some embodiments, the anionic Gemini surfactant has structure I(a) or I(b).






[0040] In some embodiments of the present disclosure, the anionic Gemini surfactant has the following structure (II):



Structure (II)

[0041] In structure (II), X_3 and X_4 are integers, each independently having a value of four to twenty; specifically four to 12, such as seven to 11, more specifically any of 4, 5, 6, or 7. Z_1 and Z_2 are integers, each independently having a value of zero, one, two, or three. In some specific embodiments of the present disclosure, Z_1 and Z_2 are zero or one. In more specific embodiments of the present disclosure, Z_1 and Z_2 are both one. Y is a covalently bound divalent linker, which is defined above in connection with structure (I). M is the counterion or a covalently bonded moiety, which is as defined above in connection with structure (I).

[0042] In some embodiments of the present disclosure, the anionic Gemini surfactant has the following structure (III):



Structure (III)


[0043] In structure (III), X_3 and X_4 are integers, each independently having a value of four to twenty; preferably four to 12, such as seven to 11, specifically seven, or specifically such as 4, 5, 6, or 7. Z_1 and Z_2 are integers, each independently having a value of zero, one, two, or three. In specific embodiments, Z_1 and Z_2 are zero or one. In specific embodiments of the present disclosure, Z_1 and Z_2 are both one. Y_1 is an integer having a value of two and 12, preferably between four and eight. M_1 and M_2 are as defined above in connection with structure (I).

[0044] The present disclosure is additionally directed to a method of preparing a polymerizable anionic Gemini surfactant. In some embodiments, the polymerizable anionic Gemini surfactant is prepared by contacting a carboxylic acid, a carboxylate salt, or a carboxylate ester with sufficient quantity (e.g., at least two equivalents) of a base capable of deprotonating the alpha carbon of the carboxylic acid. The carboxylic acid, carboxylate salt or carboxylate ester comprises at least one carboxylate moiety, e.g., a carboxylic acid, a carboxylate anion, or a carboxylate ester (e.g., an aliphatic ester having an aliphatic group, e.g., an alkyl group, having from one to four carbon atoms, such as methyl, ethyl, isopropyl, n-propyl, isobutyl, n-butyl, or sec-butyl) and an aliphatic group generally having at least seven carbon atoms and at least one carbon-to-carbon double bond. In some embodiments, the carbon-to-carbon double bond comprises a terminal alkene, i.e., the alkene comprises the omega carbon atom and the carbon atom bonded to the omega carbon atom. In some embodiments, the carboxylic acid comprises at least two carbon-to-carbon double bonds, such as at least two conjugated carbon-to-carbon double bonds. In some embodiments, the two conjugated carbon-to-carbon double bonds comprise terminal conjugated carbon-to-carbon double bonds. Exemplary carboxylic acids include nonenoic acid (e.g., 9-nonenoic acid), decenoic acid (e.g., 9-decenoic acid), undecenoic acid (e.g., 10-undecenoic acid),

dodecenoic acid (e.g., 11-dodecenoic acid), tridecenoic acid (e.g., 12-tridecenoic acid), tetradecenoic acid (e.g., 13-tetradecenoic acid), pentadecenoic acid (e.g., 12-pentadecenoic acid), hexadecenoic acid (e.g., 15-hexadecenoic acid), oleic acid, linoleic acid, linolenic acid, stearidonic acid, eicosenoic acid, eicosatrienoic acid, arachidonic acid, rumenic acid, conjugated linoleic acid, gamma-linolenic acid, calendic acid, jacaric acid, erucic acid, nervonic acid, and the like.

[0045] The polymerizable anionic Gemini surfactant comprises at least two carboxylate groups and at least two aliphatic chains, each of the at least two aliphatic chains comprising at least seven carbon atoms and at least one carbon-to-carbon double bond, specifically at least two carbon-to-carbon double bonds, even more specifically at least two conjugated carbon-to-carbon double bonds. In one embodiment, the aliphatic chains comprise seven to 34 carbon atoms, specifically eight to 24 carbon atoms. Deprotonation of the alpha carbon of the carboxylic acid yields a carbanion that is reactive with a compound comprising leaving groups. Suitable bases include alkyl lithiums, alkylmagnesium reagents, lithium diisopropylamide, lithium tetramethylpiperidine, dialkylamide base, sodium hydride, and potassium hydride, among other suitable strong bases. The reaction suitably occurs in aprotic solvent, e.g., tetrahydrofuran, diethyl ether, an alkane solvent, an aromatic solvent, alkylamine solvents, alkyl diamine solvents, and alkyl phosphoramidate solvents.

[0046] The carboxylate compound containing the reactive carbanion is then contacted with a compound comprising the Y, covalently bound divalent linker, terminated with leaving groups, which may be depicted as follows:




wherein L₁ and L₂ comprise leaving groups, and Y covalently bound divalent linker as described above. The molar ratio is generally about 2 moles deprotonated carboxylate compound to 1 mole compound containing the Y linker, but can readily be adjusted. Exemplary leaving groups include bromide, iodide, chloride, tosylate, mesylate, triflate, benzenesulfonate, and p-toluenesulfonate. This contact thereby yields the anionic Gemini surfactants of the disclosure. In some embodiments, the anionic Gemini surfactants have the structure (I), (II) or (III).

[0047] In some embodiments of the present disclosure, a polymerizable Gemini surfactant is prepared by oxidizing an anionic Gemini surfactant comprising an alkene moiety to thereby prepare terminal aldehydes, which is followed by reaction with a reagent for converting the terminal aldehydes into terminal conjugated dienes. In some embodiments,

the Gemini surfactant is prepared by the above described enolate chemistry (i.e., deprotonation of the alpha carbon of a carboxylic acid, salt, or ester followed by reaction with a Y-containing compound with terminal leaving groups).


[0048] In some embodiments, a polymerizable anionic Gemini surfactant is prepared from an anionic Gemini surfactant starting material that is a dicarboxylate linked with a connecting moiety and further comprising at least two aliphatic groups, each comprising an alkene. In some embodiments, the anionic Gemini surfactant comprises at least two aliphatic groups, each comprising terminal alkenes. Such a compound may have the following general structure (IV):



Structure (IV)

wherein X_1 , X_2 , Y , and R_{17} through R_{22} are each independently hydrogen, fluoride, chloride, bromide, C_1 to C_8 alkyl, C_2 to C_8 alkenyl, tri(C_1 - C_4 alkyl)silyl, and substituted or unsubstituted phenyl, and M_1 and M_2 carry the definitions set forth for structures (I), (II) and (III).1.



[0049] In some embodiments, a Gemini dicarboxylate compound comprising aliphatic groups comprising alkenes, e.g., terminal alkenes, such as the compound depicted in structure (IV), may be contacted with an oxidizing agent to oxidize the alkene into a terminal carbonyl and thereby prepare a Gemini dialdehyde having the general structure (V):




wherein X_1 , X_2 , Y , and M_1 and M_2 are as defined above in connection with structures (I)-(III).

[0050] The alkenes, e.g., terminal alkenes, of the Gemini dicarboxylate surfactant may be oxidized with an oxidizing agent selected from among ozone, oxygen, and metallic oxides such as metallic tetraoxides. Exemplary metallic tetraoxides include potassium permanganate (KMnO_4), ruthenium tetraoxide (RuO_4), and osmium tetraoxide (OsO_4). Oxidation proceeds, for example, by contacting the anionic Gemini surfactants having Structure IV with excess metal tetraoxide in any non-alcohol solvent in which the alkene is soluble. The temperature is, for example, -100°C to $+100^\circ\text{C}$. Oxidation with gaseous oxidants such as ozone and oxygen may be conducted in a variety of solvents in which the alkene is soluble at temperatures of -100°C to $+100^\circ\text{C}$.


[0051] In some embodiments, the Gemini dialdehyde is contacted with a reagent capable of converting the terminal aldehydes into terminal conjugated dienes to thereby prepare the polymerizable Gemini surfactant. The polymerizable Gemini surfactant may take either the trans or cis isomer depending upon the subsequent workup, i.e., acidic or alkaline. In general, such polymerizable Gemini surfactants have the following structures (VIa) or (VIb):



wherein X_1 , X_2 , Y , and M_1 and M_2 are as defined above in connection with Structures (I), (II), and (III). The disclosure also includes polymers in which one diene is cis and the other is trans, e.g. polymers of structure (VIc)




[0052] In some embodiments, the reagent capable of converting the terminal aldehydes into terminal conjugated dienes comprises an allylboronic acid or an ester thereof, such as a 1-trialkylsilyl)allyl-3-boronic acid or an ester thereof. In one embodiment, the allylboronic acid or ester thereof has the following structure:




wherein R_{23} , R_{24} , R_{25} , and R_{26} are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, chelating alkyl, or aryl. R_{23} , R_{24} , R_{25} , and R_{26} comprise 3 to 20 carbon atoms. Specific allylboronic acid esters include (1-trialkylsilyl)allyl-3-boronic acid pinacol ester, (1-trialkylsilyl)allyl-3-boronic acid catechol ester. In some embodiments, the reagent comprises Matteson's reagent. Exemplary (1-trialkylsilyl)allyl-3-boronic acid pinacol esters include allylboronic acid pinacol ester, allylboronic catechol ester, allylboronic acid diethyl ester, allylboronic acid 1,2-ethanediol ester, and allylboronic acid 1,3-propanediol ester.

[0053] In some embodiments, the reagent capable of converting the terminal aldehydes into terminal conjugated diene comprises a Wittig reagent or a modified Wittig reagent. In some embodiments, the Wittig reagent comprises triphenyl phosphonium ylide, having the general structure:



wherein R_{27} and R_{28} are each independently hydrogen, an aliphatic, e.g., alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, or an aryl or substituted aryl. R_{27} and R_{28} comprise 3 to 20 carbon atoms. In some embodiments, the Wittig reagent comprises R_{27} comprising $-\text{CH}=\text{CH}_2$ and R_{28} comprising hydrogen. In such embodiments, the Wittig reagent may be used to prepare a terminal conjugated diene. In some embodiments, the Wittig reagent comprises R_{27} comprising $-\text{CH}=\text{CH}-\text{CH}=\text{CH}_2$ and R_{28} comprising hydrogen. In such embodiments, the Wittig reagents may be used to prepare a terminal conjugated triene.


[0054] In some embodiments, the reagent capable of converting the terminal aldehydes into terminal conjugated diene comprises a phosphonate carbanion. In some embodiments, the reagent has the general structure:




wherein R_{29} and R_{30} are each independently hydrogen, an aliphatic, e.g., alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, or an aryl or substituted aryl. R_{29} and R_{30} comprise 3 to 20 carbon atoms. EWG is an electron withdrawing group and may provide the conjugated alkenyl moiety. In some embodiments, the phosphonate carbanion reagent comprises EWG comprising R_{29} comprising $-\text{CH}=\text{CH}_2$ and R_{30} comprising hydrogen. In such embodiments, the phosphonate carbanion reagent may be used to prepare a terminal conjugated diene. In some embodiments, the reagent comprises the Horner-Wadsworth-Emmons reagent.


[0055] Contact with the reagent, suitably, an allylboronic acid or ester thereof, is followed by an elimination reaction, e.g., a silanol elimination reaction. The use of other reagents, e.g., Wittig type reagents or phosphonate carbanions, involve eliminations of the phosphorus-containing moieties. The pH of the elimination reaction influences the isomerism of the final polymerizable Gemini surfactant. An acidic workup (e.g., sulfuric acid in tetrahydrofuran) generally yields substantially more trans isomer than cis, such as at least about 60:40 trans:cis, at least about 80:20 trans:cis, at least about 90:10 trans:cis, or even at least about 95:5 trans:cis. An alkaline workup (e.g. potassium hydroxide in tetrahydrofuran) generally yields substantially more trans isomer than cis, such as at least about 60:40 cis:trans, at least about 80:20 cis:trans, at least about 90:10 cis:trans, or even at least about 95:5 cis:trans.

[0056] In some embodiments, the present disclosure is directed to a polymer comprising a cross-linked or polymerized anionic Gemini surfactant. The anionic Gemini surfactant comprises at least two carboxylate moieties and at least two aliphatic moieties. Additionally, at least two of the aliphatic chains comprise at least seven carbon atoms and at least one pair of conjugated carbon-to-carbon double bonds. In some embodiments, the polymerizable anionic Gemini surfactant according to the present disclosure has the structure (I):



wherein X_1 , X_2 , Y , M_1 , M_2 , Z_1 , Z_2 , and R_1 through R_{10} are as defined above. The polymer comprising the polymerized anionic Gemini surfactant is thus polymerized from an anionic Gemini surfactant having structure (I). The polymer comprises 1 to 10^{25} , 10 to 10^{23} , 10 to 10^{15} , 10 to 10^6 , or 10 to 10^4 units of the anionic Gemini surfactant. In some embodiments the surfactant is any one of the following:





[0057] In some embodiments, the polymer comprises a cross-linked anionic Gemini surfactant polymerized from an anionic Gemini surfactant having any of structures (II), (III), (VIa), (VIb), and (VIc) all as described above.

[0058] The polymerized anionic Gemini surfactant may be in a form of a porous polymer film. The present disclosure is therefore further directed to a polymer, which may be in the form of a porous polymer film or membrane comprising polymerized anionic Gemini surfactants according to the present disclosure. In some embodiments, the present disclosure provides bulk materials comprising polymers formed from the anionic Gemini surfactants of the present disclosure. The polymers may be formed in nearly any dimension or geometry. In some embodiments, the thickness of the membrane or bulk material may be about 1 micrometers to about 5 millimeters, such as about 10 micrometers to about 5 millimeters.

[0059] The membranes may be formed as a film between two plates (the plates may be transparent if cross-linking is achieved through photopolymerization), or may be formed on or within a porous support. The support may be of a suitable material known to those skilled in the art including polymers, metals, and ceramics. In some embodiments, the support is a porous polymeric material. In some embodiments, the porous support is polyethylene (including high molecular weight and ultra-high molecular weight polyethylene), polyacrylonitrile (PAN), polyacrylonitrile-co-polyacrylate, polyacrylonitrile-co-methacrylate, polysulfone (Psf), Nylon 6, 6, poly(vinylidene difluoride) or polycarbonate. Methods for forming composite membranes comprising polymers according to the present disclosure attached to a porous support are described in PCT/US2003/031429 and U.S. Patent Application Publication US 2006/0096922 by Gin et al., hereby incorporated by reference for their disclosure of methods to form composite membranes. In some embodiments, the composite membrane comprising polymerized anionic Gemini surfactant and a porous

support may be prepared by applying anionic Gemini surfactant monomer to the support followed by polymerization. Solvents may include organic solvent, water, or another polar solvent; and an optional polymerization initiator. Application of the solution to the support can be achieved by any solution based process known to the art, including painting, rolling, spraying and inkjet printing of the solution onto the support. The solution is applied to form a coating on at least a portion of the surface of the support. The solvent may be evaporated from the film by allowing the solvent to evaporate at ambient temperature. Temperatures and controlled atmospheres as known by those skilled in the art can be used to evaporate the solvent from the film.

[0060] In some embodiments, the polymer comprising polymerized Gemini surfactants is formed on network glasses, particularly silicate glass, fluoride glass, aluminosilicates, phosphate glasses, borate glasses, and chalcogenide glass. The polymer comprising polymerized Gemini surfactants may be formed on metal substrates, e.g., copper, aluminum, zinc, etc. for use as, for example, ion transport films in batteries.

[0061] In some embodiments, the polymerized Gemini surfactants may be polymerized into a cross-linked network with substantial retention of the original LLC phase microstructure. In some embodiments, the present disclosure provides polymer membranes comprising lyotropic liquid crystal polymers formed from the anionic Gemini surfactants of the present disclosure. That is, the anionic Gemini surfactants may be mixed with a suitable solvent to thereby prepare a lyotropic liquid crystal phase, which may then be polymerized. The solution to prepare the lyotropic liquid crystal may optionally further contain a polymerization initiator. Some embodiments of the present disclosure are directed to polymerized anionic Gemini surfactant in a form of a triply periodic multiply continuous lyotropic phase. In some embodiments, the triply periodic multiply continuous lyotropic phase comprises a gyroid phase (space group #230). In some embodiments, the triply periodic multiply continuous lyotropic phase comprises a double diamond phase (space group #224). In some embodiments, the triply periodic multiply continuous lyotropic phase comprises a primitive cubic phase (space group #229). In some embodiments, the triply periodic multiply continuous lyotropic phase comprises a hexagonal tetracircular phase (space group #193) (space group #193) with percolating pores in three dimensions.

[0062] The present disclosure is further directed to a lyotropic liquid crystal composition prepared by polymerizing a polymerizable anionic Gemini surfactant having an LLC phase. The LLC phase may be prepared by combining a polymerizable anionic Gemini surfactant according to the present disclosure and a suitable polar solvent, preferably a polar,

protic solvent. Exemplary polar solvents, including polar, protic solvents, are selected from water, ethylene glycol, diethylene glycol, glycidol, 2-butene-1,4-diol, propanediol, glycerol, formamide, N-methylformamide, N,N-dimethylformamide, N-ethylformamide, acetamide, N-methylacetamide, N-ethylacetamide, methanol, ethanol, propanol, ethylammonium nitrate, ethanolammonium nitrate, ethyl ammonium formate, ethanolammonium formate, ethylammonium acetate, ethanolammonium acetate, 1-ethyl-3-methyl-imidazolium acetate, 1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide, 1-ethyl-3-methylimidazolium tetrafluoroborate, or any combination thereof, with water being particularly preferred. The lyotropic liquid crystal composition of the present disclosure prepared by combining a polymerizable anionic Gemini surfactant and polar, protic solvent are capable of robustly forming a variety of lyotropic liquid crystal phases. The polymerizable anionic Gemini surfactants of the present disclosure are capable of forming triply periodic multiply continuous phases over a broad range of concentrations and temperatures. These triply periodic multiply continuous phases encompass bicontinuous cubic phases known in the art, for example, the gyroid phase (space group #230), double diamond phase (space group #224), or primitive cubic phase (space group #229). The triply periodic multiply continuous phases of the present disclosure additionally encompass tetracontinuous phases, such as a novel hexagonal tetracontinuous phase (space group #193) with percolating pores in three dimensions. The pores in these materials may range from 5-100 Å. See FIG. 1.

[0063] In some embodiments, the polymerizable anionic Gemini surfactant forms a triply periodic multiply continuous phase such as a gyroid phase (space group #230), double diamond phase (space group #224), primitive cubic phase (space group #229), or hexagonal tetracontinuous phase (space group #193) over a range of concentrations from C_i to C_{ii} wherein the difference between C_i and C_{ii} is at least 10 weight percent, at least 12 weight percent, at least 14 weight percent, at least 16 weight percent, at least 18 weight percent, or at least 20 weight percent. Advantageously, the three dimensional multiply continuous phase is stable over a broad range of temperatures from T_i to T_{ii} wherein the difference between T_i and T_{ii} is at least 40°C, at least 45°C, at least 50°C, at least 55°C, at least 60°C, at least 65°C, at least 70°C, at least 75°C, or at least 80°C.

[0064] According to empirical results to date, the polymerizable anionic Gemini surfactant forms a triply periodic multiply continuous phase at concentrations of at least 5 weight percent, specifically at least 10 weight percent. In some embodiments, the concentration of the polymerizable anionic Gemini surfactant are higher, such as at least 40

weight percent, at least 45 weight percent, or at least 50 weight percent. At these concentrations, the lyotropic liquid crystal phase generally transitions from hexagonal to Q-phase. At anionic Gemini surfactant concentrations generally no greater than 90 weight percent, no greater than 85 weight percent, or no greater than 80 weight percent, the lyotropic liquid crystal phase generally transitions from Q-phase to lamellar. The concentrations at which these phase transitions occur depend upon multiple factors, in addition to concentration. These factors include the structure of the anionic Gemini surfactant, the identity of the counterion, the temperature of the system, the pressure of the system, and the presence and identity of co-solvents, if any are added to the system. In view thereof, the concentrations of the phase transition may vary significantly from one surfactant to another. The anionic Gemini surfactants comprising at least one, and specifically two, carboxylate groups of the present disclosure advantageously provide robust LLC systems exhibiting triply periodic multiply continuous phases over broad concentration and temperature ranges.

[0065] The solvent concentration is generally at least 5 weight percent, specifically at least 10 weight percent, in order to prepare a lyotropic liquid crystal. At concentrations less than about 5 weight percent or less than about 10 weight percent, the anionic Gemini surfactant generally forms a crystalline phase. In specific embodiments, the solvent is water. The solvent optionally includes additional solvents, generally in low concentrations, such as less than 10 weight percent, specifically less than 5 weight percent. For example, the surfactant may be introduced into the LLC phase pre-dissolved in a solvent in which the surfactant is soluble. Suitable solvents for pre-dissolving the surfactants may include methanol, ethanol, acetone, tetrahydrofuran, diethyl ether, glycerol, ethylene glycol, dimethylformamide, and combinations thereof.

[0066] The polymers of the present disclosure, which include lyotropic liquid crystal compositions, comprising polymerizable anionic Gemini surfactants may be polymerized by chemically crosslinking the polymerizable anionic Gemini surfactant with a suitable polymerization agent. In some embodiments wherein a lyotropic liquid crystal structure is to be retained, the polymerizable anionic Gemini surfactant to be polymerized by chemical crosslinking may be any of the liquid crystal phases, e.g., hexagonal, lamellar, micellar, and even the three dimensional multiply continuous phases including the gyroid, double diamond, primitive, and hexagonal tetracontinuous phase (space group #193) with percolating pores.

[0067] In some embodiments, a polymerizable Gemini surfactant, which may be contained within a lyotropic liquid crystal, is contacted with a crosslinking agent such as a

photoinitiator. The photoinitiator is present in the mixture of Gemini surfactant and solvent, which thereby causes formation of the LLC phase. Exemplary photoinitiators are substituted acetophenones, such as 2,2-dimethoxy-2-phenylacetophenone, 2,2-diethoxyacetophenone, 2-benzyl-2-(dimethylamino)-4'-morpholinobutyrophenone, 4'-tert-butyl-2',6'-dimethylacetophenone, diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide/2-hydroxy-2-methylpropiophenone, 4'-ethoxyacetophenone, 3'-hydroxyacetophenone, 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone, 2-hydroxy-2-methylpropiophenone, 2-Methyl-4'-(methylthio)-2-morpholinopropiophenone, 4'-phenoxyacetophenone, and combinations thereof.

[0068] In one embodiment, the polymer is prepared by irradiating the polymerizable Gemini surfactant to photoinitiate crosslinking of the polymerizable surfactants and thereby fix the lyotropic liquid crystal into a stable, robust structure. The lyotropic liquid crystal may be irradiated with light having a wavelength dependent upon the photoinitiator selected. In general, the wavelength is 220 nm to 600 nm.

[0069] In some embodiments, a polymerizable Gemini surfactant, which may be contained within a lyotropic liquid crystal, is contacted with a crosslinking agent such as a thermal initiator. In this embodiment, the thermal initiator is present in the mixture of Gemini surfactant and solvent, which thereby causes formation of the LLC phase. Suitable thermal initiators include azo initiators such as azobisisobutyronitrile (AIBN), 1,1'-azobis(cyclohexane-1-carbonitrile) (V-40), 2,2'-azobis(4-methoxy-2,4-dimethyl valeronitrile) (V-70), 2,2'-azobis(2,4-dimethyl valeronitrile) (V-65), dimethyl 2,2'-azobis(2-methylpropionate) (V-601), 2,2'-azobis(2-methylbutyronitrile) (V-59), 2,2'-azobis[N-(2-propenyl)-2-methylpropionamide] (VF-096), 1-[(1-cyano-1-methylethyl)azo]formamide (V-30), 2,2'-azobis(N-butyl-2-methylpropionamide) (VAm-110), and 2,2'-azobis(N-cyclohexyl-2-methylpropionamide) (VAm-111). Additional azo initiators include 2,2'-azobis[2-(2-imidazolin-2-yl)propane] (VA-061), 2,2'-azobis{2-methyl-N-[1,1-bis(hydroxymethyl)-2-hydroxyethyl]propionamide} (VA-080), and 2,2'-azobis[2-methyl-N-(2-hydroxyethyl)propionamide] (VA-086). Combinations of the foregoing azo initiators are also included. The temperature of thermal initiation depends upon the specific initiator used. In general, thermal initiation may occur at temperatures of 22°C to 150°C, specifically 60°C to 120°C.

[0070] Other exemplary initiators include peroxides, such as alkyl, dialkyl, aryl, and diaryl peroxides. In this embodiment, the peroxide is present in the mixture of Gemini surfactant and solvent, which thereby causes formation of the LLC phase. Exemplary

peroxides include tert-butyl peroxide, di-tert-butyl peroxide, benzoyl peroxide, lauroyl peroxide (LUPEROXTM), methyl ethyl ketone peroxide, acetone peroxide, and benzoyl peroxide. Peroxides are also thermal initiators which work at temperatures of 22°C to 150°C, specifically 60°C to 120°C.

[0071] In some embodiments, a polymerizable Gemini surfactant may be crosslinked by ionizing radiation (X-rays or gamma rays), without the aid of a chemical crosslinking agent. Ionizing radiation having a wavelength of about 1 nm to about 10^{-5} nm is generally suitable for crosslinking.


[0072] Current empirical results to date indicate that lyotropic liquid crystals comprising polymerized Gemini surfactants exhibit enhanced long range order compared to lyotropic liquid crystals known in the art. The long range order is demonstrated by multiple peaks in X-ray diffraction patterns obtained from the thin films of the present disclosure. X-ray diffraction patterns obtained to date exhibit multiple peaks, generally in excess of four peaks, five peaks, six peaks, seven peaks, or even eight peaks, thereby showing the retention of long range order in the thin films of the present disclosure.

[0073] The following examples illustrate specific embodiments with the scope of the present disclosure. The examples are provided for the purpose of illustration and are not to be construed as limitations of the present disclosure.

Example 1. Synthesis of Polymerizable Anionic Gemini Surfactant

[0074] The cross-linkable Gemini surfactant potassium 2,9-di((E)-undeca-8,10-dienyl)decanedioate was synthesized as shown in Scheme 1. The lithium enolate of 10-undeceneoic acid (2 equiv.) was coupled with 1,6-dibromohexane (1 equiv.) to furnish 1 with a Gemini structure bearing terminal double bonds. Esterification of 1 with MeOH was achieved under acidic conditions to furnish a Gemini diester, which was ozonolyzed to yield Gemini diester dialdehyde 2. Treatment of 2 with Matteson's reagent, followed by an exposure to H₂SO₄ effected the one-pot installation of the unsaturated dienes on both tails of the diester in 3. Basic hydrolysis of the methyl esters in 3 furnishes the unsaturated Gemini diacid, which was neutralized with K₂CO₃ to yield the desired cross-linkable Gemini surfactant 4.

Scheme 1.



[0075] This cross-linkable anionic Gemini surfactant forms lyotropic liquid crystals having the following structures from 30 wt.% to 100 wt.% in 5 wt.% increments:

35 to 55 wt.% hexagonal

55 to 65 wt.% gyroid

65 to 75 wt.% lamellar

75 to 95 wt.% primitive mesophase.

Example 2. Polymerizing a Polymerizable Anionic Gemini Surfactant

[0076] The unsaturated Gemini surfactant 4 (65 wt%) was combined with the free radical photoinitiator 2,2-dimethoxy-2-phenylacetophenone (0.4 wt%) and water (34.6 wt%) to yield a lyotropic liquid crystal (LLC). X-ray diffraction analyses of the resulting gel demonstrated that this LLC adopts a stable gyroid phase (Q^{230} space group symmetry) as shown in FIG. 3. FIG. 3 depicts azimuthally integrated X-ray diffraction patterns of a lyotropic liquid crystal (LLC) based on 65 wt% 4, 0.4 wt % 2,2-dimethoxy-2-phenylacetophenone, and 34.6 wt% H₂O. The polymerizable surfactant forms a gyroid phase before UV crosslinking (bottom curve). The XRD of the LLC after UV crosslinking (upper curve) demonstrates retention of the gyroid morphology with a slight reduction in the unit cell dimensions.

[0077] The gel was crosslinked by the following protocol. The stiff LLC gel was pressed between two circular quartz plates with a Teflon spacer (< 2 mm thickness) to yield a flat gel with near constant thickness, and this sandwich geometry was secured using 2-3 binder clips to mitigate water loss. The sample sandwich was placed on a heating block thermostatted at 50°C and irradiated for 1 hour, using a UV lamp (Ultra Violet Products UVGL-15) with a peak wavelength of 365 nm that was placed 1 cm above the top of the

sample. Upon cooling to room temperature and disassembly of the sample sandwich, a crosslinked film was isolated as ascertained by its complete insolubility in water. See FIG. 4. The morphology of the resulting film was analyzed by X-ray diffraction and shown to retain the gyroid structure with a slight reduction in the size of the unit cell. See FIG. 3. The long-range structural order of the crosslinked gyroid phase is exhibited by the eight scattering maxima in the XRD patterns for this film.

[0078] A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, $-(\text{CH}_2)\text{C}_3\text{-C}_8\text{cycloalkyl}$ is attached through carbon of the methylene (CH_2) group.

[0079] The term “substituted”, as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom’s normal valence is not exceeded. “Optionally substituted” means substituted or unsubstituted. When the substituent is oxo (i.e., $=\text{O}$) then 2 hydrogens on the atom are replaced. When an oxo group substitutes aromatic moieties, the corresponding partially unsaturated ring replaces the aromatic ring. For example a pyridyl group substituted by oxo is a pyridone. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture. Unless otherwise specified substituents are named into the core structure. For example, it is to be understood that when (cycloalkyl)alkyl is listed as a possible substituent the point of attachment of this substituent to the core structure is in the alkyl portion.

[0080] Suitable groups that may be present on a “substituted” position include, but are not limited to, e.g., halogen; cyano; hydroxyl; nitro; azido; $-\text{COOH}$, $-\text{SO}_3\text{H}$, amino, $-(\text{C}=\text{O})\text{NH}_2$, alkanoyl (such as a $\text{C}_2\text{-C}_6$ alkanoyl group such as acyl or the like); carboxamido; alkyl groups (including cycloalkyl groups) having 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 8, or 2 to about 6 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to about 8, or from 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those having one or more thioether linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those having one or more sulfinyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfonyl groups including those having one or more sulfonyl linkages and from 1 to about 8 carbon atoms, or from 1 to about

6 carbon atoms; aminoalkyl groups including groups having one or more N atoms and from 1 to about 8, or from 1 to about 6 carbon atoms; aryl having 6 or more carbons and one or more rings, (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted aromatic); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyl being an exemplary arylalkyl group; arylalkoxy having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyloxy being an exemplary arylalkoxy group; or a saturated, unsaturated, or aromatic heterocyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O or S atoms, e.g. coumarinyl, quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl. Such heterocyclic groups may be further substituted, e.g. with hydroxyl, alkyl, alkoxy, halogen and amino.


[0081] As used herein, when a definition is not otherwise provided, “substituted” indicates replacement of one or more hydrogen atoms of a group with a substituent selected from a C₁ to C₆ alkyl group, a C₁ to C₆ hydroxyalkyl group, a C₂ to C₆ alkenyl group, a C₂ to C₆ alkynyl group, a C₃-C₇ cycloalkyl group, a C₃ to C₇ cycloalkenyl group, a cycloalkynyl group, a heterocycloalkyl group, halogen (Br, F or Cl), a haloalkyl group, an alkoxy group, a halogen (F, Cl, Br, or I), a hydroxyl group (OH), an acid group (-COOH), -PO₃H₂, -SO₃H, -OSO₃H, a nitro group (-NO₂), a cyano group (-CN), an amino group (-NR'₂ wherein each R' is independently a hydrogen or a C₁ to C₆ alkyl group), a carbonyl group (-C(=O)-), a carbamyl group, or an ester group (-C(=O)OR'' wherein R'' is a C₁ to C₆ alkyl group or a C₆ to C₁₀ aryl group), a carboxyl group (-C(=O)OH) or a salt thereof, and a combination thereof.

[0082] An “aliphatic group” is organic chemical group in which the carbon atoms are linked in open chains, such as alkanes, alkenes and alkynes. An aliphatic group may be branched or unbranched and may also be a non-aromatic cyclic group such as a cyclohexyl or cyclohexenyl group or may include both cyclic and acyclic groups. An aliphatic group may be entirely hydrocarbon (hydrocarbyl) in composition or may be substituted with non-hydrocarbon substituents. An “alkyl” group is a straight or branched chain saturated aliphatic hydrocarbyl group having the specified number of carbon atoms, a valence of one, and optionally substituted with one or more substituents where indicated.


[0083] An “alkenyl” group is a straight or branched chain hydrocarbyl group having the specified number of carbon atoms, a valence of one, at least one carbon-carbon double bond, and optionally substituted with one or more substituents where indicated.

[0084] An “alkynyl” group is a straight or branched chain hydrocarbon having the specified number of carbon atoms a valence of one, at least one carbon-carbon triple bond, and optionally substituted with one or more substituents where indicated.

[0085] “Amino acid side chains” include, but are not limited to, the side chains of the 20 common naturally occurring amino acids, e.g.



[0086] In certain embodiments “amino acid side chain” does not include the proline side chain.



[0087] A “cycloalkyl” group is a hydrocarbyl group having one or more saturated rings in which all ring members are carbon, the specified number of carbon atoms, a valence

of one, and optionally substituted with one or more substituents where indicated. Non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and adamantyl groups. Cycloalkyl groups do not contain an aromatic ring or a heterocyclic ring.

[0088] An “aryl” group is a carbocyclic ring system that includes one or more aromatic rings in which all ring members are carbon, having the specified number of carbon atoms, a valence of one, and optionally substituted with one or more substituents where indicated and having. More than one ring may be present, and any additional rings may be independently aromatic, saturated, or partially unsaturated and multiple rings, if present, may be fused, pendent, spirocyclic or a combination thereof. Non-limiting examples include phenyl, naphthyl, and tetrahydronaphthyl groups. “Phenyl” means a six-membered aromatic ring.

[0089] “Heteroaryl” indicates a stable monocyclic aromatic ring having the indicated number of ring atoms which contains from 1 to 3, or in some embodiments from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5- to 7-membered aromatic ring which contains from 1 to 3, or in some embodiments from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon. Monocyclic heteroaryl groups typically have from 5 to 7 ring atoms. In some embodiments bicyclic heteroaryl groups are 9- to 10-membered heteroaryl groups, that is, groups containing 9 or 10 ring atoms in which one 5- to 7-member aromatic ring is fused to a second aromatic or non-aromatic ring. When the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heteroaryl group is not more than 2. It is particularly preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl groups include, but are not limited to, oxazolyl, pyranyl, pyrazinyl, pyrazolopyrimidinyl, pyrazolyl, pyridiziny, pyridyl, pyrimidinyl, pyrrolyl, quinoliny, tetrazolyl, thiazolyl, thienylpyrazolyl, thiophenyl, triazolyl, benzo[d]oxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxadiazolyl, dihydrobenzodioxynyl, furanyl, imidazolyl, indolyl, and isoxazolyl.

[0090] A “heterocyclic ring” is a saturated, unsaturated, or aromatic ring group having at least one ring containing a heteroatom chosen from N, O, and S, with remaining ring atoms being carbon.

[0091] Examples of heterocyclic rings include pyridyl, dihydropyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized

tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinoliny, isoquinoliny, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinoliny, tetrahydroisoquinoliny, decahydroquinoliny, octahydroisoquinoliny, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranly, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indoliziny, isoindolyl, 3H-indolyl, 1H-indazolyl, purinyl, 4H-quinoliziny, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnoliny, pteridinyl, 4aH-carbazolyl, carbazolyl, β -carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazoliny, pyrazolidinyl, pyrazolinyl, piperazinyl, indoliny, isoindoliny, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazoliny, isatinoyl, and bis-tetrahydrofuranyl.

[0092] As used herein, when a definition is not otherwise provided, the prefix “hetero” means that the group has 1 to 3 heteroatoms independently selected from N, O, S, P, Si, and B, and a combination thereof. “Heteroaliphatic” includes an aliphatic group as defined herein, with at least one heteroatom in the aliphatic chain. In cyclic groups, 1 to 3 heteroatoms can be present as a ring member. For example, a pyridyl is C₅ heteroaryl group, and an “alkoxy” group is a heteroalkyl group where an alkyl moiety is linked via an oxygen (e.g., methoxy). In a cyclic group the following heteroatoms may be used: N, O, and S.

[0093] While the stereochemistry of the various compounds is not explicitly shown, it is to be understood that this disclosure encompasses all isomers.


[0094] When referring to the molecular weight of a polymer, the term molecular weight refers to number-averaged molecular weight (M_n).

[0095] Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention as used herein.

[0096] While the invention has been described with reference to various embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims. Any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

WHAT IS CLAIMED IS:

1. A polymerizable anionic Gemini surfactant having the following structure:



wherein X_1 and X_2 are each independently an optionally substituted branched, unbranched, or cyclic aliphatic groups having from four to 30 carbon atoms;

Z_1 and Z_2 are integers, each independently having a value of zero, one, two, or three;

Y is a covalently bound divalent linker;

M_1 and M_2 are the same or different and are each independently selected from hydrogen, hydroxyl, $-O(C_1-C_8 \text{ alkyl})N(CH_3)_3^+(X^-)$ where X^- is a counterion, $-(C_0-C_8 \text{ alkyl})NR_{11}R_{12}$, $-O(C_1-C_8 \text{ alkyl})NR_{11}R_{12}$, $-NH(C_1-C_8 \text{ alkyl})NR_{11}R_{12}$, $-NH(CH-R_{13})COOH$, $-OR_{11}$, $-NR_{11}R_{14}$, and $-O^-(M^+)$ where M^+ is a counterion, wherein R_{11} , R_{12} , and R_{14} are independently chosen from hydrogen and optionally substituted C_1-C_8 alkyl, and wherein R_{13} is an amino acid side chain; and

R_1 through R_{10} are each independently chosen from hydrogen, fluoride, chloride, bromide, C_1-C_8 alkyl, C_2-C_8 alkenyl, $\text{tri}(C_1-C_4 \text{ alkyl})\text{silyl}$, and substituted or unsubstituted phenyl.

2. The surfactant of Claim 1, wherein

M_1 and M_2 are the same or different and at least one M_1 or M_2 is a covalently bonded group selected from $-OCH_2CH(OH)CH_2OH$, $-NH(C_1-C_8 \text{ alkyl})SO_3H$, $-N(CH_3)(C_1-C_8 \text{ alkyl})SO_3H$, $-O(C_1-C_8 \text{ alkyl})SO_3H$, $-NH(C_1-C_8 \text{ alkyl})OSO_3H$, $-N(CH_3)(C_1-C_8 \text{ alkyl})OSO_3H$, $-O(C_1-C_8 \text{ alkyl})OSO_3H$, $-NH(C_1-C_8 \text{ alkyl})PO_3H_2$, $-N(CH_3)(C_1-C_8 \text{ alkyl})PO_3H_2$, and $-O(C_1-C_8 \text{ alkyl})PO_3H_2$.

3. The surfactant of claim 1, wherein Z_1 and Z_2 each independently have a value of zero or one.

4. The surfactant of claim 1, wherein each of M^+ is independently selected at each occurrence from the group consisting of lithium ion; sodium ion; potassium ion; cesium ion; zinc ion; magnesium ion; calcium ion; ammonium ion; alkylammonium ion having the structure $H_xR_{4-x}N^+$ wherein x is an integer having a value of 0 through 4 and R is selected from the group consisting of methyl, ethyl, propyl, butyl, and combinations thereof;

tetrakis(hydroxymethyl)phosphonium ion; tetramethylphosphonium ion; choline; imidazolium; bis(quaternary ammonium) ion; and combinations thereof.

5. The surfactant of claim 1, wherein

Y is a covalently bound, divalent linker chosen from:

an optionally substituted C₁-C₂₀ aliphatic group, an optionally substituted C₁-

C₂₀heteroaliphatic group, which aliphatic and heteroaliphatic groups may be branched, unbranched, or cyclic;


an optionally substituted aryl or heteroaryl group, comprising 1 aromatic ring or 2 or 3 fused rings of which at least one ring is aromatic, wherein each aromatic ring in the aryl or heteroaryl group contains 5-6 ring atoms, with 0-4 heteroatoms independently chosen from N, O, and S with remaining ring atoms being carbon, and each non-aromatic ring in the aryl or heteroaryl group contain 3-7 ring atoms with 0 to 2 heteroatoms independently chosen from N, O, and S and remaining ring atoms being carbon, and wherein the aryl or heteroaryl group optionally comprises one or two C₁-C₅ aliphatic chains wherein the point of attachment of Y is a carbon in the C₁-C₅aliphatic chain; and

an optionally substituted poly(C₁-C₁₀ alkyl)ether of the formula

-C₀-C₃alkyl-(O-C₁-C₁₀ alkyl)_n-O-C₀-C₃alkyl or an optionally substituted poly(C₁-C₁₀ alkylcarboxamide) of the formula -C₀-C₃ alkyl-((C=O)NH-C₁-C₁₀ alkyl)_n-(C=O)NH-C₀-C₃ alkyl, where n is an integer from 1 to 4.

6. The surfactant of Claim 5, wherein Y is a divalent poly(C₁-C₃ alkyl)ether of the formula C₀-C₃ alkyl-(O-C₁-C₃ alkyl)_n-O-C₀-C₃ alkyl, where n is an integer from 1 to 4, which is optionally substituted with one or more substituents independently chosen from hydroxy, oxo, C₁-C₃ alkyl, and C₁-C₃ alkoxy.

7. The surfactant of claim 1, having the structure:




wherein X_3 and X_4 are integers, each independently having a value of four to twenty.

8. The surfactant of claim 7, wherein X_3 and X_4 each independently have a value of four to 11.

9. A method of preparing a polymerizable Gemini surfactant comprising:


(a) contacting a carboxylic acid, a carboxylate salt, or a carboxylate ester with a quantity of a base to thereby deprotonate the alpha carbon of the carboxylic acid, carboxylate salt, or carboxylate ester, wherein the carboxylic acid, carboxylate salt, or carboxylate ester comprises at least seven carbon atoms and at least one carbon-to-carbon double bond; and

(b) contacting the alpha carbon-deprotonated carboxylic acid, carboxylate salt, or carboxylate ester of (a) with a compound having the structure:



wherein L_1 and L_2 comprise leaving groups and Y comprises a covalently bound divalent linker, whereby said contacting forms the Gemini surfactant.

10. The method of claim 9, wherein the Gemini surfactant has the following structure:



wherein X_1 and X_2 are each independently a an optionally substituted, branched, unbranched or cyclic group aliphatic moiety having from four to 30 carbon atoms;

Z_1 and Z_2 are integers, each independently having a value of zero, one, two, or three;

Y is a covalently bound divalent linker;

M_1 and M_2 are the same or different and are each independently selected from hydrogen, hydroxyl, $-\text{O}(\text{C}_1\text{-C}_8 \text{ alkyl})\text{N}(\text{CH}_3)_3^+(\text{X}^-)$ where X^- is a counterion, $-(\text{C}_0\text{-C}_8 \text{ alkyl})\text{NR}_{11}\text{R}_{12}$, $-\text{O}(\text{C}_1\text{-C}_8 \text{ alkyl})\text{NR}_{11}\text{R}_{12}$, $-\text{NH}(\text{C}_1\text{-C}_8 \text{ alkyl})\text{NR}_{11}\text{R}_{12}$, $-\text{NH}(\text{CH-R}_{13})\text{COOH}$, $-\text{OR}_{11}$, $-\text{NR}_{11}\text{R}_{14}$, and $-\text{O}^-(\text{M}^+)$ where M^+ is a counterion, wherein R_{11} , R_{12} , and R_{14} are

independently chosen from hydrogen and optionally substituted C₁-C₈ alkyl, and wherein R₁₃ is an amino acid side chain; and

R₁ through R₁₀ are each independently hydrogen, fluoride, chloride, bromide, C₁ to C₈ alkyl, C₂ to C₈ alkenyl, tri(C₁-C₄ alkyl)silyl, and substituted or unsubstituted phenyl.

11. The method of claim 10, wherein each of M₁ and M₂ are each independently a group -O⁻(M⁺), where M⁺ is a counterion selected from the group consisting of lithium ion; sodium ion; potassium ion; cesium ion; zinc ion; magnesium ion; calcium ion; ammonium ion; alkylammonium ion having the structure H_xR_xN⁺ wherein x is an integer having a value of 0 through 4 and R is selected from methyl, ethyl, propyl, and butyl, and combinations thereof; tetrakis(hydroxymethyl)phosphonium ion; tetramethylphosphonium ion; choline; imidazolium; bis(quaternary ammonium) ion; and combinations thereof.

12. The method of claim 9, wherein Y is a covalently bound, divalent linker chosen from:

an optionally substituted C₁-C₂₀aliphatic group, an optionally substituted C₁-


C₂₀heteroaliphatic group, which aliphatic and heteroaliphatic groups may be branched, unbranched, or cyclic;

an optionally substituted aryl or heteroaryl group, comprising 1 aromatic ring or 2 or 3 fused rings of which at least one ring is aromatic, wherein each aromatic ring in the aryl or heteroaryl group contains 5-6 ring atoms, with 0-4 heteroatoms independently chosen from N, O, and S with remaining ring atoms being carbon, and each non-aromatic ring in the aryl or heteroaryl group contain 3-7 ring atoms with 0 to 2 heteroatoms independently chosen from N, O, and S and remaining ring atoms being carbon, and wherein the aryl or heteroaryl group optionally comprises one or two C₁-C₅ aliphatic chains wherein the point of attachment of Y is a carbon in the C₁-C₅aliphatic chain; and

an optionally substituted poly(C₁-C₁₀alkyl)ether of the formula


-C₀-C₃alkyl-(O-C₁-C₁₀alkyl)_n-O-C₀-C₃alkyl or an optionally substituted poly(C₁-C₁₀alkylcarboxamide) of the formula -C₀-C₃alkyl-((C=O)NH-C₁-C₁₀alkyl)_n-(C=O)NH-C₀-C₃alkyl, where n is an interger from 1 to 4.

13. A method of preparing a Gemini surfactant comprising a terminal diene of the formula




the method comprising:

contacting a Gemini dicarboxylate compound of Structure IV



with an oxidizing agent to thereby prepare a Gemini dialdehyde of Structure V



and

contacting the Gemini dialdehyde with a (1-trialkylsilyl)allyl-3-boronic acid or an ester thereof, which contact is followed by a silanol elimination reaction with an acid or a base to thereby prepare the Gemini surfactant comprising the terminal diene;

wherein X_1 and X_2 are each independently an optionally substituted branched, unbranched, or cyclic aliphatic group having from four to 30 carbon atoms;

Y is a covalently bound divalent linker;

M_1 and M_2 are the same or different and are each independently selected from hydrogen, hydroxyl, $-O(C_1-C_8 \text{ alkyl})N(CH_3)_3^+(X^-)$ where X^- is a counterion, $-(C_0-C_8 \text{ alkyl})NR_{11}R_{12}$, $-O(C_1-C_8 \text{ alkyl})NR_{11}R_{12}$, $-NH(C_1-C_8 \text{ alkyl})NR_{11}R_{12}$, $-NH(CH-R_{13})COOH$, $-$

OR₁₁, -NR₁₁R₁₄, and -O⁻(M⁺) where M⁺ is a counterion, wherein R₁₁, R₁₂, and R₁₄ are independently chosen from hydrogen and optionally substituted C₁-C₈ alkyl, and wherein R₁₃ is an amino acid side chain; and

R₁₇ through R₂₂ are each independently hydrogen, fluoride, chloride, bromide, C₁-C₈alkyl, C₂-C₈ alkenyl, tri(C₁-C₄ alkyl)silyl, and substituted or unsubstituted phenyl.

14. The method of claim 13, wherein the (1-trialkylsilyl)allyl-3-boronic acid or ester thereof is selected from the group consisting of allylboronic acid pinacol ester, allylboronic catechol ester, allylboronic acid diethyl ester, allylboronic acid 1,2-ethanediol ester, and allylboronic acid 1,3-propanediol ester.

15. A method of preparing a polymer comprising:
contacting the anionic Gemini surfactant of claim 1 with a polymerization initiator to thereby prepare the polymer, wherein the polymer comprises 1 to 10²⁵ units of the anionic Gemini surfactant.

16. The method of claim 15, wherein the polymerization initiator comprises a photoinitiator selected from the group consisting of 2,2-dimethoxy-2-phenylacetophenone, 2,2-diethoxyacetophenone, 2-benzyl-2-(dimethylamino)-4'-morpholinobutyrophenone, 4'-tert-butyl-2',6'-dimethylacetophenone, diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide/2-hydroxy-2-methylpropiophenone, 4'-ethoxyacetophenone, 3'-hydroxyacetophenone, 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone, 2-Hydroxy-2-methylpropiophenone, 2-Methyl-4'-(methylthio)-2-morpholinopropiophenone, 4'-phenoxyacetophenone, and combinations thereof.

17. The method of claim 16, wherein the anionic Gemini surfactant in contact with the photoinitiator is irradiated with light having a wavelength of 220 nm to 600 nm.

18. The method of claim 15, wherein the polymerization initiator comprises a thermal initiator selected from the group consisting of azobisisobutyronitrile, 1,1'-azobis(cyclohexane-1-carbonitrile), 2,2'-azobis(4-methoxy-2,4-dimethyl valeronitrile), 2,2'-azobis(2,4-dimethyl valeronitrile), dimethyl 2,2'-azobis(2-methylpropionate), 2,2'-azobis(2-methylbutyronitrile), 2,2'-azobis[N-(2-propenyl)-2-methylpropionamide], 1-[(1-cyano-1-methylethyl)azo]formamide, 2,2'-azobis(N-butyl-2-methylpropionamide), 2,2'-azobis(N-cyclohexyl-2-methylpropionamide), 2,2'-azobis[2-(2-imidazolin-2-yl)propane], 2,2'-azobis[2-methyl-N-[1,1-bis(hydroxymethyl)-2-hydroxyethyl]propionamide], 2,2'-azobis[2-methyl-N-(2-hydroxyethyl)propionamide] (VA-086), and combinations thereof.

19. A polymer comprising:

a polymerized anionic Gemini surfactant of claim 1.

20. The polymer of claim 19, wherein the cross-linked anionic Gemini surfactant in a form of a porous polymer film.

21. The polymer of claim 20, wherein the cross-linked anionic Gemini surfactant is in a form of a triply periodic multiply continuous lyotropic phase.

22. The polymer of claim 21, further comprising a polar solvent.


23. The polymer of claim 21, wherein the triply periodic multiply continuous lyotropic phase comprises a gyroid phase (space group #230).

24. The polymer of claim 21, wherein the triply periodic multiply continuous lyotropic phase comprises a double diamond phase (space group #224).


25. The polymer of claim 21, wherein the triply periodic multiply continuous lyotropic phase comprises a primitive cubic phase (space group #229).

26. The polymer of claim 21, wherein the triply periodic multiply continuous lyotropic phase comprises a hexagonal tetracontinuous phase (space group #193) with percolating pores in three dimensions.

27. The surfactant of Claim 1, having the structure



28. The surfactant of Claim 1, having the structure



wherein R_{13} is independently selected at each occurrence from the group consisting of amino acid side chains.




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F

FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3





FIG. 4



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/022701

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07C57/13 C07C69/602 C09K19/38 C09K19/02
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07C C09K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ULRICH F HEISER ET AL: "Simple and high yield synthesis of ()10,10'-dimethyl-dotriacontan-1,1'-diol as a building block for branched bola compounds. Preparation of ()10,10'-dimethyl-dotriacontan-1,1'-diyl-bis [2-(trimethylammonio)ethyl phosphate] and the corresponding unbranched equivalent", CHEMISTRY AND PHYSICS OF LIPIDS, vol. 90, no. 1-2, 1 November 1997 (1997-11-01), pages 25-30, XP055057791, ISSN: 0009-3084, DOI: 10.1016/S0009-3084(97)00073-X page 28; compound 2 ----- -/--	1,3-5, 7-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 March 2013

Date of mailing of the international search report

09/04/2013

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Duval, Eric

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/022701

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2008/089924 A1 (NOJIMA HIROSHI [JP] ET AL) 17 April 2008 (2008-04-17) figure 1; compounds MI-22, MI-39, MI-40 -----	1,3,5
X	CLAYTON H. HEATHCOCK ET AL: "Daphniphyllum alkaloids. 12. A proposed biosynthesis of the pentacyclic skeleton. proto-Daphniphylline", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 57, no. 9, 1 April 1992 (1992-04-01), pages 2554-2566, XP055058133, ISSN: 0022-3263, DOI: 10.1021/jo00035a009 page 2558; compound 48 -----	1,3,5
X	TOLSTIKOV G. A. ET AL.: "Telomerization of butadiene and isoprene with sulfones containing active methine and methylene groups, catalyzed by palladium complexes", BULLETIN OF THE ACADEMY OF SCIENCES OF THE USSR, DIVISION OF CHEMICAL SCIENCE, vol. 32, no. 3, March 1983 (1983-03), pages 529-536, XP002694671, DOI: 10.1007/BF00953090 page 533; compound X -----	1,3
Y	GREGORY P. SORENSON ET AL: "Unusually Stable Aqueous Lyotropic Gyroid Phases from Gemini Dicarboxylate Surfactants", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 133, no. 38, 28 September 2011 (2011-09-28), pages 14928-14931, XP055057781, ISSN: 0002-7863, DOI: 10.1021/ja2063555 scheme 1 -----	1-28
Y	US 2010/075195 A1 (ELLIOTT BRIAN [US] ET AL) 25 March 2010 (2010-03-25) figure 19 -----	1-28
A	US 2006/096922 A1 (GIN DOUGLAS L [US] ET AL) 11 May 2006 (2006-05-11) cited in the application the whole document -----	1-28
A	US 2004/211939 A1 (ELLIOTT BRIAN [US]) 28 October 2004 (2004-10-28) the whole document -----	1-28
	----- -/--	

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/022701

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	SAMBASIVARAO KOTHA ET AL: "Diversity-Oriented Approach to Macrocyclic Cyclophane Derivatives via Ring-Closing Metathesis", SYNLETT, vol. 23, no. 15, 31 August 2012 (2012-08-31), pages 2183-2188, XP055058116, ISSN: 0936-5214, DOI: 10.1055/s-0032-1317020 page 2184; compound 13d -----	1,3,5, 7-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/022701

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2008089924 A1	17-04-2008	JP 4884231 B2	29-02-2012
		US 2008089924 A1	17-04-2008
		WO 2006049157 A1	11-05-2006

US 2010075195 A1	25-03-2010	US 2007218371 A1	20-09-2007
		US 2010075195 A1	25-03-2010

US 2006096922 A1	11-05-2006	AU 2003279793 A1	29-07-2004
		US 2006096922 A1	11-05-2006
		WO 2004060531 A1	22-07-2004

US 2004211939 A1	28-10-2004	NONE	
